Adaptimmune Therapeutics plc

ADAPY

US00653A1079

Pharmaceuticals

Market Closed - OTC Markets 15:51:35 2026-09-18 EDT			5-day change	1st Jan Change
0.0225 ^USD	-2.17%		-0.66%	-13.46%

05-18	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI

Top Midday Decliners

Published on 10/20/2025 at 12:22 pm EDT

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Adaptimmune Therapeutics plc

05-18	Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-17	Adaptimmune Therapeutics plc Announces CEO Changes	CI
11-17	Adaptimmune Therapeutics plc Announces Leadership Changes	CI
25-10-27	Evaxion Names Helen Tayton-Martin as Chief Executive Officer	MT
25-10-26	Adaptimmune Therapeutics plc(OTCPK:ADAP.Y) dropped from NASDAQ Composite Index	CI
25-10-24	European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading	MT
25-10-23	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
25-10-22	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
25-10-21	European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	MT
25-10-20	Top Midday Decliners	MT
25-10-20	European Equities Close Mostly Higher in Monday Trading; UK Sentiment Sees 'Some of the Gloom Lift'	MT
25-10-20	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
25-10-20	Adaptimmune Therapeutics to Voluntarily Delist From Nasdaq	MT
25-10-17	European Equities Traded in the US as American Depositary Receipts Down in Friday Trading, Up for Week	MT
25-10-16	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT

Chart Adaptimmune Therapeutics plc

Duration

Period

ADAPY: Dynamic Chart

Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.

Employees

272

Sector

Pharmaceuticals

More about the company